Reverse share split effective 30 May

On 23 May 2011 the Annual General Meeting in DiaGenic ASA resolved to carry out a reverse share split in the ratio 10:1, by an increase of the shares' nominal value with NOK 0.45 from NOK 0.05 to NOK 0.50, so that 10 shares are consolidated into 1 share. The reverse share split will be effective on Monday 30 May 2011 (ex consolidation). The last trading day prior to the reverse share split is Friday 27 May 2011. Post the reverse share split, the company's share capital will be NOK 13,511,826, divided into 27,023,652 shares, each with a nominal value of NOK 0.50.

Contact:

Erik Christensen, CEO

Telephone: 47 95939918

e-mail: erik.christensen@diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts of the body. DiaGenic has developed and CE marked two blood based diagnostic tests, BCtect® for early breast cancer detection and ADtect® for early detection of Alzheimer’s Disease. The company protects its technology through an extensive patent portfolio. DiaGenic promotes its products towards leading pharmaceutical and imaging companies, and towards clinicians. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com